NCT06738251View on ClinicalTrials.gov

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2027

Conditions
Advanced Urothelial Carcinoma
Interventions
DRUG

SHR-A2102 for Injection

SHR-A2102 for Injection.

DRUG

Docetaxel Injection

Docetaxel Injection.

DRUG

Paclitaxel Injection

Paclitaxel Injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for Injection.

DRUG

Pemetrexed Disodium for Injection

Pemetrexed Disodium for Injection.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY